CLAIMS

1. The use of a nanoliposome in the manufacture of a medicament for the prophylaxis and/or treatment of anterior segment ocular diseases, wherein the nanoliposome comprises a plurality of unsaturated and/or saturated lipids forming at least one lipid bilayer encapsulating a hydrophobic drug comprising tacrolimus, and wherein the hydrophobic drug and the plurality of unsaturated and/or saturated lipids have a weight ratio of up to 0.2; wherein the plurality of unsaturated and/or saturated lipids comprise at least one unsaturated lipid constituting more than 50 wt% of the at least one lipid bilayer and which comprise 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC).

2. The use according to claim 1, wherein the nanoliposome has a drug loading of up to 1 mg/ml.

3. The use according to claim 1 or 2, wherein the nanoliposome has an average size of 80 nm to 150 nm before storage at 4°C.

4. The use according to any one of claims 1 to 3, wherein the nanoliposome has an average size of 90 nm to 120 nm after storage at 4°C.

5. The use according to any one of claims 1 to 4, wherein the nanoliposome has a polydispersity index of less than 0.3 before and after storage.

6. The use according to any one of claims 1 to 5, wherein the nanoliposome is a multilamellar vesicle or an unilamellar vesicle.

7. The use according to any one of claims 1 to 6, wherein the plurality of unsaturated and/or saturated lipids consists of POPC.

8. A nanoliposome for use in the prophylaxis and/or treatment of anterior segment ocular diseases, wherein the nanoliposome comprises a plurality of

unsaturated and/or saturated lipids forming at least one lipid bilayer encapsulating a hydrophobic drug comprising tacrolimus, and wherein the hydrophobic drug and the plurality of saturated and/or unsaturated lipids have a weight ratio of up to 0.2; wherein the plurality of unsaturated and/or saturated lipids comprise at least one unsaturated lipid constituting more than 50 wt% of the at least one lipid bilayer and which comprise 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC).

9. The nanoliposome according to claim 8, wherein the nanoliposome has a drug loading of up to 1 mg/ml.

10. The nanoliposome according to claim 8 or 9, wherein the nanoliposome has an average size of 80 nm to 150 nm before storage at 4°C.

11. The nanoliposome according to any one of claims 8 to 10, wherein the nanoliposome has an average size of 90 nm to 120 nm after storage at 4°C.

12. The nanoliposome according to any one of claims 8 to 11, wherein the nanoliposome has a polydispersity index of less than 0.3 before and after storage.

13. The nanoliposome according to any one of claims 8 to 12, wherein the nanoliposome is a multilamellar vesicle or an unilamellar vesicle.

14. The nanoliposome according to any one of claims 8 to 13, wherein the plurality of unsaturated and/or saturated lipids consists of POPC.